文献速递慢性肾脏病肾血管病与高血压血液净化与透析

强化与标准降压对需透析或肾移植长期发生率的遗留效应

The Legacy Effect of Intensive versus Standard BP Control on the Incidence of Needing Dialysis or Kidney Transplantation.
PubMed 文献 · J Am Soc Nephrol · 2024-07-30

SPRINT试验的二次分析纳入9279例高血压且心血管高危患者,随机接受收缩压<120 mmHg强化治疗或<140 mmHg标准治疗,中位随访8.6年。强化治疗未显著增加肾衰竭(透析或移植)风险,总体风险比1.20(95%CI 0.81–1.78),基线eGFR<45亚组风险比1.43(95%CI 0.89–2.30)。

要点

  • 强化降压未显著增加长期需透析或肾移植的风险。
  • 肾衰竭事件多数发生在基线eGFR<45的患者中。
  • 强化治疗组肾衰竭发生率数值上较高但差异无统计学意义。

核心结论

  • 强化降压总体及基线eGFR<45亚组中需透析或肾移植率数值上高于标准治疗,但差异无统计学意义。

研究设计与样本

  • 随机开放标签临床试验的二次分析,纳入9279例50岁以上高血压且心血管高危患者,随机分至收缩压<120 mmHg或<140 mmHg目标,并进行观察性随访。

主要发现

  • 中位随访8.6年(四分位距8.0–9.1年)共发生101例肾衰竭,其中74例(73.3%)基线eGFR<45 ml/min per 1.73 m2。
  • 强化治疗总体肾衰竭原因特异性风险比1.20(95%CI 0.81–1.78)。
  • 基线eGFR<45亚组强化治疗肾衰竭原因特异性风险比1.43(95%CI 0.89–2.30)。

临床怎么用

  • 强化降压至收缩压<120 mmHg时,应关注基线肾功能,尤其eGFR<45患者的肾衰竭风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: In the Systolic Blood Pressure Intervention Trial (SPRINT), the longer-term incidence of needing dialysis or transplantation was low and primarily associated with baseline kidney function. Rates of dialysis or transplantation were higher with intensive versus standard treatment, though the differences were not statistically significant. BACKGROUND: The Systolic Blood Pressure Intervention Trial (SPRINT) showed that intensive lowering of systolic BP increased the risk of incident CKD and episodes of AKI. Whether intensive treatment changes the risk of kidney failure is unknown. The goal of this study was to estimate the legacy effect of intensive versus standard systolic BP lowering on the longer-term incidence of kidney failure. METHODS: This study is a secondary analysis of a randomized, open-label clinical trial with observational follow-up. Between 2010 and 2013, patients 50 years and older with hypertension and higher cardiovascular risk excluding those with diabetes mellitus, history of stroke, proteinuria >1 g/d, or polycystic kidney disease were recruited from 102 clinic sites in the United States and Puerto Rico. Participants were randomized to a systolic BP goal of <120 mm Hg (intensive treatment) or <140 mm Hg (standard treatment group). We linked participants with the United States Renal Data System to ascertain kidney failure (initiation of dialysis therapy or transplantation) and the US National Death Index to ascertain all-cause mortality through 2020. RESULTS: Based on analysis of 9279 (99.1%) of 9361 randomized participants, 101 cases of kidney failure occurred over a median follow-up of 8.6 years (interquartile range, 8.0–9.1 years), with the majority occurring in 74 (73.3%) participants with an eGFR <45 ml/min per 1.73 m2 at baseline. Intensive treatment did not significantly increase the risk of kidney failure either overall (cause-specific hazard ratio, 1.20; 95% confidence interval, 0.81 to 1.78) or in the subgroup of participants with baseline eGFR <45 ml/min per 1.73 m2 (cause-specific hazard ratio, 1.43; 95% confidence interval, 0.89 to 2.30). CONCLUSIONS: Overall, and in patients with eGFR <45 ml/min per 1.73 m2, there were higher rates of dialysis or transplantation among SPRINT participants randomized to intensive treatment, but the modest differences observed were not statistically significant. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:: SPRINT, NCT01206062.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Pajewski NM, Beddhu S, Bress AP, et al. The Legacy Effect of Intensive versus Standard BP Control on the Incidence of Needing Dialysis or Kidney Transplantation. J Am Soc Nephrol. 2024. PMID: 39078712. doi:10.1681/ASN.0000000000000459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。